166 related articles for article (PubMed ID: 33091218)
1. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
[TBL] [Abstract][Full Text] [Related]
2. Liver fat accumulation is associated with circulating PCSK9.
Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients.
Shyamala N; Gundapaneni KK; Galimudi RK; Tupurani MA; Padala C; Puranam K; Kupsal K; Kummari R; Gantala SR; Nallamala KR; Sahu SK; Hanumanth SR
J Gene Med; 2021 Aug; 23(8):e3346. PubMed ID: 33885177
[TBL] [Abstract][Full Text] [Related]
4. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
[TBL] [Abstract][Full Text] [Related]
5. Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol.
Ioannou GN; Lee SP; Linsley PS; Gersuk V; Yeh MM; Chen YY; Peng YJ; Dutta M; Mascarinas G; Molla B; Cui JY; Savard C
Hepatol Commun; 2022 Apr; 6(4):780-794. PubMed ID: 34816633
[TBL] [Abstract][Full Text] [Related]
6. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition.
Momtazi-Borojeni AA; Banach M; Ruscica M; Sahebkar A
Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1199-1208. PubMed ID: 36193738
[TBL] [Abstract][Full Text] [Related]
7. What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.
Qiu C; Zeng P; Li X; Zhang Z; Pan B; Peng ZYF; Li Y; Ma Y; Leng Y; Chen R
Lipids Health Dis; 2017 Jun; 16(1):111. PubMed ID: 28606094
[TBL] [Abstract][Full Text] [Related]
8. A promising therapy for fatty liver disease: PCSK9 inhibitors.
Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
[TBL] [Abstract][Full Text] [Related]
9. Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis.
Liu S; Wan J; Wang D; Yang Y; Fang J; Luo T; Liang D; Hu J; Hou J; Wang P
Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1339-1351. PubMed ID: 38734541
[TBL] [Abstract][Full Text] [Related]
10. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
[TBL] [Abstract][Full Text] [Related]
11. R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Mostaza JM; Lahoz C; Salinero-Fort MA; de Dios O; Castillo E; González-Alegre T; García-Iglesias F; Estirado E; Laguna F; Sabín C; López S; Cornejo V; de Burgos C; Sanchez V; Garcés C;
J Clin Lipidol; 2018; 12(4):1039-1046.e3. PubMed ID: 29773421
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
Baragetti A; Balzarotti G; Grigore L; Pellegatta F; Guerrini U; Pisano G; Fracanzani AL; Fargion S; Norata GD; Catapano AL
Eur J Prev Cardiol; 2017 Nov; 24(17):1870-1877. PubMed ID: 28758421
[TBL] [Abstract][Full Text] [Related]
13. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.
Verbeek R; Boyer M; Boekholdt SM; Hovingh GK; Kastelein JJ; Wareham N; Khaw KT; Arsenault BJ
Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):43-48. PubMed ID: 27856457
[TBL] [Abstract][Full Text] [Related]
14. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
Bonnefond A; Yengo L; Le May C; Fumeron F; Marre M; Balkau B; Charpentier G; Franc S; Froguel P; Cariou B;
Diabetologia; 2015 Sep; 58(9):2051-5. PubMed ID: 26049403
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways.
Huang P; Ran J; Zhu W; Dai W; Tang Y; Lian P; Huang X; Li R
FASEB J; 2024 Feb; 38(4):e23464. PubMed ID: 38358343
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
[TBL] [Abstract][Full Text] [Related]
17. A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
Di Filippo M; Vokaer B; Seidah NG
J Clin Lipidol; 2017; 11(4):1101-1105. PubMed ID: 28711549
[TBL] [Abstract][Full Text] [Related]
18. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
20. Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration.
Wanneh E; Luna G; Dufour R; Baass A
J Clin Lipidol; 2017; 11(1):55-60. PubMed ID: 28391911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
